ReviewThe treatment and prognosis of dermatomyositis: An updated review
Section snippets
Corticosteroids
Adults with DM who have active, confirmed muscle disease are generally given systemic corticosteroids. High-dose corticosteroids (>0.5 mg/kg/d) are the mainstay of treatment for this disease. The American Academy of Dermatology (AAD) recommends systemic corticosteroids for initial control of muscle disease and, in most instances, a sufficient initial dose should be 0.5 to 1.5 mg/kg/d. After the muscle disease is controlled, the dose can be tapered slowly.7 The AAD did not address specific taper
Dermatologic manifestations
In DM, the dermatologic manifestations are often difficult to treat. They may have a discordant response to therapy from the muscle disease, and can continue to be refractory to treatment after muscle weakness has resolved.32 To treat skin manifestations, the AAD7 recommends aggressive sun protection with physical barriers and sunscreen, and topical corticosteroids.
Hydroxychloroquine has been used in treating DM, which is endorsed by the AAD.7 Woo et al128 treated 7 patients with variations of
Prognosis
As treatments for DM have changed, so has the prognosis. It is important to identify prognostic factors, as these may eventually help improve treatments for patients with specific characteristics of DM. Mortality has varied from 8.9% to 52%,24, 51, 148, 149, 150 however, the large range may be a result of disease variation across patients. The disease subtypes Bohan and Peter4 identified are frequently analyzed together. Duration of follow-up can also affect the perceived prognosis. One-year
Our approach to the treatment of patients with DM
Our view is that the majority of patients with DM can experience long-lasting remissions (>20 years follow-up in many patients) off therapy if the treatment of the DM is initially aggressive, and then is gradually tapered over 2 to 3 years without allowing muscle disease (as assessed by muscle enzymes, clinical evaluation of proximal extensor muscle strength, and other standard measurements) to flare (ie, flares are rapidly and completely suppressed). The dermatologic disease, unfortunately for
References (168)
Therapeutic targets in patients with inflammatory myopathies: present approaches and a look to the future
Neuromuscul Disord
(2006)- et al.
Polymyositis and dermatomyositis
Lancet
(2003) Idiopathic inflammatory myopathy: management and prognosis
Rheum Dis Clin North Am
(2002)- et al.
Prognosis in adult polymyositis
J Neurol Sci
(1975) - et al.
Presentation, treatment, and prognosis of idiopathic inflammatory muscle disease in a rural hospital
Am J Med
(1983) - et al.
Drug therapy of the idiopathic inflammatory myopathies: Predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy
Am J Med
(1993) - et al.
Dermatomyositis: a dermatology-based case series
J Am Acad Dermatol
(1998) - et al.
Course of treated juvenile dermatomyositis
J Pediatr
(1984) - et al.
Childhood dermatomyositis: clinical course of 36 patients treated with low doses of corticosteroids
Eur J Paediatr Neurol
(1998) - et al.
Pulsed intravenous methylprednisolone therapy for inflammatory myopathies: evaluation of the effect by comparing two consecutive biopsies from the same muscle
J Neuroimmunol
(1997)
Failure of pulse intravenous methylprednisolone treatment in juvenile dermatomyositis
J Pediatr
High-dose intravenous methyl-prednisolone in chronic polymyositis/dermatomyositis
Brain Dev
Treatment of dermatomyositis with methotrexate
J Am Acad Dermatol
Low-dose methotrexate administered weekly is an effective corticosteroid-sparing agent for the treatment of the cutaneous manifestations of dermatomyositis
J Am Acad Dermatol
Adult-onset polymyositis-dermatomyositis: Description of 25 patients with emphasis on treatment
Semin Arthritis Rheum
Cyclosporin in juvenile dermatomyositis
Lancet
The use of intravenous immune globulin in collagen vascular disorders: a potentially new modality of therapy
J Allergy Clin Immunol
Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients
Am J Med
Treatment of dermatomyositis with intravenous gammaglobulin
Am J Med
The role of high-dose immune globulin intravenous in the treatment of dermatomyositis
Int Immunopharmacol
Interstitial lung disease in polymyositis and dermatomyositis: clinical course and response to treatment
Semin Arthritis Rheum
Dermatomyositis
Polymyositis, dermatomyositis and inclusion-body myositis
N Engl J Med
Inflammatory myopathies: Clinical, diagnostic and therapeutic aspects
Muscle Nerve
Polymyositis and dermatomyositis (two-part article)
N Engl J Med
Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis
Cochrane Database Syst Rev
Guidelines of care for dermatomyositis: American Academy of Dermatology
J Am Acad Dermatol
Review article: a therapeutic update on dermatomyositis/polymyositis
Int J Dermatol
Treatment of polymyositis and dermatomyositis
Curr Opin Rheumatol
The management of lupus erythematosus, scleroderma, lichen sclerosus and dermatomyositis
Clin Exp Dermatol
Treatment of idiopathic inflammatory myopathies
Curr Opin Neurol
Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis
Medicine (Baltimore)
Survival in polymyositis: corticosteroids and risk factors
J Rheumatol
Course of dermatomyositis-polymyositis: comparison of untreated and cortisone-treated patients
Mayo Clin Proc
Polymyositis/dermatomyositis: clinical features and outcome in 22 patients
J Rheumatol
Influence of age at onset on the duration of treatment in idiopathic adult polymyositis and dermatomyositis
Arch Intern Med
Relationship between serum creatine kinase level and corticosteroid therapy in polymyositis-dermatomyositis
J Rheumatol
Polymyositis-dermatomyositis: 25 years of follow-up of 50 patients disease course, treatment, prognostic factors
Mater Med Pol
Polymyositis and dermatomyositis: short term and long term outcome, and predictive factors of prognosis
J Rheumatol
Disease course, frequency of relapses and survival of 73 patients with juvenile or adult dermatomyositis
Clin Exp Rheumatol
Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients
Medicine (Baltimore)
Juvenile dermatomyositis: clinical, laboratorial, histological, therapeutical and evolutive parameters of 35 patients
Arq Neuropsiquiatr
Outcome in juvenile dermatomyositis
Indian Pediatr
A retrospective study of 13 oriental children with juvenile dermatomyositis
Ann Acad Med Singapore
Juvenile dermatomyositis
Indian J Pediatr
Frequency of relapses in patients with polymyositis and dermatomyositis
Muscle Nerve
National registry of patients with juvenile idiopathic inflammatory myopathies in Hungary–clinical characteristics and disease course of 44 patients with juvenile dermatomyositis
Autoimmunity
Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality
Rheumatology (Oxford)
Drug therapy in juvenile dermatomyositis: follow-up study
J Child Neurol
Cited by (81)
Cutaneous dermatomyositis disease course followed over time using the Cutaneous Dermatomyositis Disease Area and Severity Index
2018, Journal of the American Academy of DermatologyThe systemic management of cutaneous dermatomyositis: Results of a stepwise strategy
2017, International Journal of Women's DermatologyThe rash that presents as a red swollen face
2020, Clinics in DermatologyProgressive Interstitial Lung Disease in a Clinically Quiescent Dermatomyositis
2023, Acta Medica PhilippinaDermatomyositis
2022, Interdisciplinary Approaches to Overlap Disorders in Dermatology and Rheumatology
Funding sources: None.
Conflicts of interest: None declared.